Slovo úvodem

Ing. Tomáš Kocourek, Ph.D.

Psychiatr. praxi 2017; 18(1)  

Research of new drugs for Alzheimer’s disease

PharmDr. Jana Hroudová, Ph.D.

Psychiatr. praxi 2017; 18(1): 7-10 | DOI: 10.36290/psy.2017.002  

Alzheimer’s disease (AD) is the most common cause of dementia, however, the treatment AD options are limited and based on administration of cholinesterase inhibitors and/or memantine, affecting glutamatergic system. Presented review article summarizes current approaches in the research of novel agents for AD treatment; it is focused on the molecules reaching the clinical trials. The most developed direction of pharmacotherapy is focused on pathologic β-amyloid (Aβ). Several perspective studies testing monoclonal Aβ antibodies and β-secretase inhibitors are ongoing. Further, new cholinesterase inhibitors, monoamine oxidase inhibitors,...

Long-acting injectable antipsychotics for prevention and management of violent behavior and aggression in patients with psychosis

prof. MUDr. Pavel Mohr, Ph.D., MUDr. Pavel Knytl, Mgr. Veronika Voráčková, MUDr. Anna Bravermanová, MUDr. Tomáš Melicher

Psychiatr. praxi 2017; 18(1): 12-16 | DOI: 10.36290/psy.2017.003  

Although aggressive and violent behavior is not a typical manifestation of schizophrenia or other psychotic disorders, psychosis increases the risk of violence. One of the modifiable factors of violence is adherence with medication. Long-term antipsychotic treatment prevents relapse, lowers number of rehospitalizations, and also effectively reduces violent and aggressive behavior. By contrast, nonadherence with drug treatment and subsequent relapse potentially increases risk of violent and aggressive acts. Nonadherence can be addressed partially by long-acting injectable antipsychotics (LAI). Empirical evidence from clinical practice, post-hoc...

Clozapine in the treatment of bipolar disorder

prof. MUDr. Klára Látalová, Ph.D.

Psychiatr. praxi 2017; 18(1): 17-20 | DOI: 10.36290/psy.2017.004  

The growing number of studies shows that clozapine is useful in the treatment of mood disorders either with psychotic symptoms or without psychotic symptoms, and especially in the treatment of resistant bipolar disorder. It has been found that the use of clozapine in bipolar disorder is significantly associated with a reduced number of psychiatric hospitalization reduction additives psychotropics and minor pumping health care due to self-harming or overdose. It is highly likely that clozapine has strong mood stabilizing effects. Clozapine has more than other antipsychotics, specific “anti-aggressive effect” and has sedative effects...

Psychiatric issues of children born preterm

MUDr. Tereza Michálková Grézlová, MUDr. Daniela Marková, doc. PhDr. et PhDr. Radek Ptáček, Ph.D., MUDr. Michal Goetz, Ph.D.

Psychiatr. praxi 2017; 18(1): 21-25  

Preterm birth is a significant risk factor for number of psychiatric disorders and neurodevelopmental impairments. However, mental health issues of preterm children are substantially underestimated in comparison with that somatic. This article has several objectives: to summarize the most important findings of preterm mental health studies, to inform briefly about the recent research on preterm children born with very low birthweight and to draft concept of psychological and psychiatric care for children with serious perinatal stress.

Choice of pharmacotherapy in patient s with schizophrenia and co-occurring substance use

prof. MUDr. Eva Češková, CSc., PharmDr. Lenka Sušilová, MUDr. Libor Ustohal, Ph.D.

Psychiatr. praxi 2017; 18(1): 26-29 | DOI: 10.36290/psy.2017.006  

Substance use disorder is the most frequent comorbidity in patients suffering from schizophrenia. It is associated with more frequent and longer hospitalizations and others indicators of a poor outcome. Further, schizophrenia with comorbid substance use disorder (dual diagnosis) is characterized by a high non-adherence and frequent somatic diseases. The main treatment is represented by antipsychotics. Especially clozapine may decrease the craving and amount of the abused substance. In spite of the high frequency and clinical consequences we have at our disposal very few controlled studies and particularly in the long-term treatment of schizophrenia...

Case report of a patient with Huntington’s disease

MUDr. Marie Hojgrová, Mgr. Monika Víchová, MUDr. Bc. Libor Ustohal, Ph.D., MUDr. Michaela Mayerová

Psychiatr. praxi 2017; 18(1): 38-41 | DOI: 10.36290/psy.2017.008  

This case study describes a 59-year-old patient with a neuropsychiatric disorder – Huntington’s disease. The patient had been treated by psychiatrists for a long time, finally he was hospitalized at the Department of Psychiatry of the University hospital for suspicion of obsessive compulsive disorder. During hospitalization, the patient was properly examined by a neurologist. Also, the family history was completed because until then was unclear. Based on these steps, a suspicion on Huntington’s disease was officially pronounced. The patient was ordered to genetic testing and handed over to the care of specialized neurological...

Dementia of the Alzheimer’s Type

MUDr. Vanda Franková

Psychiatr. praxi 2017; 18(1): 30-33  

This article presents a brief practical approach to the diagnosis and treatment of dementia of the Alzheimer’s type.

Bio-psycho-social approach offers more understanding

MUDr. Vladislav Chvála, MUDr. David Skorunka, Ph.D.

Psychiatr. praxi 2017; 18(1): 42-46 | DOI: 10.36290/psy.2017.040  

The article deals with psychosomatic perspective and bio-psycho-social model in medicine. In the introduction, several obstacles in development of psychosomatic medicine are briefly mentioned.Then, a case study is presented to highlight some aspects of therapy process and application of bio-psycho-social model in clinical practice including integrative therapy and interdisciplinary team collaboration.